BioSpace News Archive

Prior to the Annual General Meeting in 2022, Orexo has appointed a Nomination Committee which represents approximately 38 percent of the number of votes in the company as of September 30, 2021.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in November 2021.

United Therapeutics Corporation announced that Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company’s business during a fireside chat session at the Credit Suisse 30th Annual Healthcare Conference.

In honor of American Diabetes Month®, the American Diabetes Association® and DaVita are coming together to educate Americans about the connection between diabetes and kidney disease.

AlivaMab Discovery Services, a leader in the discovery of superior antibody therapeutics, announced an expanded agreement with IGM Biosciences.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced that it will be presenting two scientific posters at the 14th Annual Clinical Trials on Alzheimer’s Disease conference to be held on November 9-12, 2021 in Boston, MA, USA.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it will release financial results for the third quarter ended September 30, 2021 before the open of trading on Monday, November 15.

Novavax, Inc. and Serum Institute of India Pvt. Ltd. announced that the National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan, has granted emergency use authorization for Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and December.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that the company will release its financial results for the third quarter ended September 30, 2021, including a corporate update, on Thursday, November 4, 2021, before market open.